| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CUTTING EDGE |
* Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
Pathology and Diagnostics, Genentech Incorporated, South San Francisco, CA 94080; and
Aging Research Center, G. D’Annunzio University Foundation, Chieti, Italy
TNF apoptosis-inducing ligand is attracting considerable interest as a potential extrinsic tumor suppressor mechanism, although previous reports have conveyed somewhat contrasting views regarding the likely importance of this pathway. In this study, we provide the first evaluation of spontaneous tumor formation over the life span of TRAIL-deficient mice. Interestingly, >25% of these mice do develop lymphoid malignancies after 500 days of life. TRAIL suppressed the initiation and development of both tumors of lymphoid and stromal origin in the context of the loss of at least one p53 allele. Specific examination of the role of TRAIL in Her2/neu oncogene-driven mammary epithelial cancer revealed no critical role for TRAIL despite the inherent TRAIL sensitivity of such mammary carcinomas. Overall, the data indicate an important function of TRAIL in controlling carcinogenesis, but suggest that further examination of this pathway in epithelial malignancies is warranted.
This article has been cited by other articles:
|
|
 |
|
  K. H. Young, D. D. Weisenburger, B. J. Dave, L. Smith, W. Sanger, J. Iqbal, E. Campo, J. Delabie, R. D. Gascoyne, G. Ott, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma Blood, December 15, 2007; 110(13): 4396 - 4405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vitovski, J. S. Phillips, J. Sayers, and P. I. Croucher Investigating the Interaction between Osteoprotegerin and Receptor Activator of NF-{kappa}B or Tumor Necrosis Factor-related Apoptosis-inducing Ligand: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS J. Biol. Chem., October 26, 2007; 282(43): 31601 - 31609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bin, J. Thorburn, L. R. Thomas, P. E. Clark, R. Humphreys, and A. Thorburn Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding J. Biol. Chem., September 21, 2007; 282(38): 28189 - 28194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Yang, N. ud Din, D. D. Browning, S. I. Abrams, and K. Liu Targeting Lymphotoxin {beta} Receptor with Tumor-Specific T Lymphocytes for Tumor Regression Clin. Cancer Res., September 1, 2007; 13(17): 5202 - 5210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E.A. Street, N. Zerafa, M. Iezzi, J. A. Westwood, J. Stagg, P. Musiani, and M. J. Smyth Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma Cancer Res., June 1, 2007; 67(11): 5454 - 5460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. F. Gajewski On the TRAIL Toward Death Receptor-Based Cancer Therapeutics J. Clin. Oncol., April 10, 2007; 25(11): 1305 - 1307. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
